Data may position Viking as next major M&A target in obesity

Viking could become the next major takeout target for pharmas looking to enter the obesity space after Phase II data for the biotech’s dual GLP-1/GIPR agonist impressed investors.

Viking Therapeutics Inc. (NASDAQ:VKTX) reached an all-time high of $90 on Tuesday before closing at $85.05, up 121%, after once-weekly subcutaneous VK2735 led to placebo-adjusted weight loss of up to 13.1% at the highest, 15 mg, dose after 13 weeks of treatment. ...